• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Global Infectious Diseases Partnering 2010-2015: Deal trends, players and financials

  • ID: 2190608
  • June 2015
  • Region: Global
  • 800 pages
  • CurrentPartnering

The Global Infectious Diseases Partnering 2010-2015 report provides an understanding and access to the infectious diseases partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter infectious diseases partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors infectious diseases technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest infectious diseases agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This READ MORE >

Note: Product cover images may vary from those shown

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in infectious diseases dealmaking

2.1. Introduction
2.2. Infectious diseases partnering over the years
2.3. Infectious diseases partnering by deal type
2.4. Infectious diseases partnering by industry sector
2.5. Infectious diseases partnering by stage of development
2.6. Partnering by infectious diseases specific technology type

Chapter 3 - Average financial deal terms for infectious diseases partnering

3.1. Introduction
3.2. Disclosed financials terms for infectious diseases partnering
3.3 Infectious diseases partnering headline values
3.4 Infectious diseases deal upfront payments
3.5 Infectious diseases deal milestone payments
3.6 Infectious diseases royalty rates

Chapter 4 - Leading infectious diseases deals

4.1. Introduction
4.1. Most active in infectious diseases partnering
4.2. Top infectious diseases deals by value
4.3. Big pharma infectious diseases dealmaking activity
4.4. Big biotech infectious diseases dealmaking activity

Chapter 5 - Infectious diseases contracts directory

5.1. Introduction
5.2. Infectious diseases partnering by company A-Z
5.3. Infectious diseases partnering stage of development
5.4. Infectious diseases partnering by deal type
5.6. Infectious diseases partnering by technology type

Appendices

Introduction
Appendix 1 - Directory of infectious diseases deals by company A-Z 2010-2015-
Appendix 2 - Directory of infectious diseases deals by stage of development 2010-2015
Appendix 3 - Directory of infectious diseases deals by deal type 2010-2015
Appendix 4 - Directory of infectious diseases deals by therapy area 2010-2015
Appendix 5 - Infectious diseases partnering resource center
About

Table of figures

Figure 1: Infectious diseases partnering since 2010
Figure 2: Infectious diseases partnering by deal type since 2010
Figure 3: Infectious diseases partnering by industry sector since 2010
Figure 4: Infectious diseases partnering by stage of development since 2010
Figure 5: Infectious diseases partnering by disease type since 2010
Figure 6: Infectious diseases partnering by specific technology type since 2010
Figure 7: Infectious diseases deals with a headline value - by stage of development
Figure 8: Infectious diseases deals with upfront payment values - by stage of development
Figure 9: Infectious diseases deals with milestone payment - by stage of development
Figure 10: Infectious diseases deals with royalty rates
Figure 11: Active infectious diseases dealmaking activity- 2010 to 2015
Figure 12: Top infectious diseases deals by value since 2010
Figure 13: Big pharma - top 50 - infectious diseases deals 2010 to 2015
Figure 14: Big pharma infectious diseases deal frequency - 2010 to 2015
Figure 15: Big biotech - top 50 - infectious diseases deals 2010 to 2015
Figure 16: Big biotech infectious diseases deal frequency - 2010 to 2015
Figure 17: Online partnering resources
Figure 18: Forthcoming partnering events

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

AB Sciex Eli Lilly and Company B. Braun Melsungen AG Astellas Pharma, Inc. Hologic Corporation Merck & Co., Inc.